Compare IBG & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBG | SXTP |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.6M |
| IPO Year | 2022 | 2023 |
| Metric | IBG | SXTP |
|---|---|---|
| Price | $0.90 | $0.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.70 |
| AVG Volume (30 Days) | 31.4K | ★ 354.5K |
| Earning Date | 05-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,005,471.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.49 |
| 52 Week Low | $0.65 | $0.34 |
| 52 Week High | $6.28 | $8.62 |
| Indicator | IBG | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 48.83 |
| Support Level | $0.76 | $0.84 |
| Resistance Level | $0.96 | $1.00 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 70.61 | 85.68 |
Innovation Beverage Group Ltd is a developer, manufacturer and exporter of a growing portfolio of 75 formulations across 14 alcoholic and non-alcoholic brands of beverages such as Australian Bitters company. It has two reportable segments: Australia and the United States. The Australia segment mainly consists of its Australian beverage operations and corporate activities, while the United States segment consists of the operations of its United States subsidiaries. Majority of revenue comes from Australia. Its brands are Australian Bitters Company, Bittertales Aromatic, Twisted Shaker Cocktails, Drummerboy Non Alcoholic Spirits, and Wired For Wine.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.